PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+22.61%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$167M
AUM Growth
+$27M
(+19%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
7.6%
Top 10 Holdings %
Top 10 Hldgs %
31.97%
Holding
144
New
17
Increased
44
Reduced
36
Closed
12
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Venus Concept
VERO
|
+$1.51M |
| 2 |
FlexShopper
FPAY
|
+$1.49M |
| 3 |
IRIDEX
IRIX
|
+$1.16M |
| 4 |
Sensus Healthcare
SRTS
|
+$1.09M |
| 5 |
Natera
NTRA
|
+$940K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IVTY
Invuity, Inc
IVTY
|
+$1.22M |
| 2 |
Tactile Systems Technology
TCMD
|
+$1.09M |
| 3 |
Flexion Therapeutics, Inc.
FLXN
|
+$1.08M |
| 4 |
Cibus
CBUS
|
+$833K |
| 5 |
OIG
Orbital Infrastructure Group, Inc. Common Stock
OIG
|
+$544K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.9% |
| 2 | Technology | 12.86% |
| 3 | Industrials | 6.55% |
| 4 | Communication Services | 4.39% |
| 5 | Consumer Discretionary | 4.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Axogen
AXGN
$2.08B
| $13.2M | 7.94% |
359,000
-6,675
| -2% | -$291K |
2013 Q3
20 quarters
|
|
2
Vericel Corp
VCEL
$2.06B
| $7.78M | 4.67% |
549,750
-2,350
| -0.4% | -$27.6K |
2014 Q3
16 quarters
|
|
3
CareDx
CDNA
$3.39B
| $6.09M | 3.66% |
211,060
+9,500
| +5% | +$178K |
2017 Q3
4 quarters
|
|
4
Abbott
ABT
$178B
| $5.65M | 3.39% |
77,050
| – | – |
2014 Q1
18 quarters
|
|
5
NeoGenomics
NEO
$2.18B
| $4.36M | 2.62% |
283,900
-5,900
| -2% | -$81.5K |
2013 Q2
21 quarters
|
|
6
Idexx Laboratories
IDXX
$41.5B
| $3.33M | 2% |
13,350
| – | – |
2013 Q3
20 quarters
|
|
|
7
Sensus Healthcare
SRTS
$48.6M
| $3.33M | 2% |
396,836
+149,950
| +61% | +$1.09M |
2018 Q2
1 quarter
|
|
8
Apyx Medical
APYX
$107M
| $3.3M | 1.98% |
465,350
+64,650
| +16% | +$359K |
2015 Q1
14 quarters
|
|
9
Champions Oncology
CSBR
$66.7M
| $3.15M | 1.89% |
180,600
+77,600
| +75% | +$691K |
2018 Q2
1 quarter
|
|
|
TEUM
10
DELISTED
Pareteum Corporation
TEUM
| $3.03M | 1.82% |
1,008,729
+190,000
| +23% | +$512K |
2017 Q1
6 quarters
|
|
11
Pfizer
PFE
$168B
| $2.98M | 1.79% |
71,218
+422
| +0.6% | +$16.2K |
2013 Q2
21 quarters
|
|
12
OptimizeRx
OPRX
$156M
| $2.8M | 1.68% |
155,450
-1,668
| -1% | -$21K |
2018 Q2
1 quarter
|
|
|
CSII
13
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.71M | 1.63% |
69,250
+900
| +1% | +$33.3K |
2013 Q2
21 quarters
|
|
14
AtriCure
ATRC
$2.91B
| $2.67M | 1.6% |
76,250
+5,000
| +7% | +$158K |
2013 Q2
21 quarters
|
|
15
Eli Lilly
LLY
$1.08T
| $2.53M | 1.52% |
23,610
| – | – |
2013 Q2
21 quarters
|
|
16
LeMaitre Vascular
LMAT
$1.88B
| $2.5M | 1.5% |
64,400
-150
| -0.2% | -$5.41K |
2017 Q1
6 quarters
|
|
|
17
Tactile Systems Technology
TCMD
$503M
| $2.45M | 1.47% |
34,505
-18,119
| -34% | -$1.09M |
2017 Q4
3 quarters
|
|
18
Magnite
MGNI
$3.42B
| $2.45M | 1.47% |
680,500
+159,000
| +30% | +$562K |
2018 Q2
1 quarter
|
|
19
DELISTED
BioLife Solutions
BLFS
| $2.44M | 1.46% |
139,150
-18,650
| -12% | -$369K |
2014 Q2
17 quarters
|
|
20
Microsoft
MSFT
$3.97T
| $2.38M | 1.43% |
20,810
| – | – |
2014 Q1
18 quarters
|
|
|
VRAY
21
DELISTED
ViewRay, Inc.
VRAY
| $2.22M | 1.33% |
237,550
+80,200
| +51% | +$788K |
2018 Q2
1 quarter
|
|
22
DELISTED
Tile Shop Holdings
TTSH
| $2.11M | 1.27% |
295,600
+40,600
| +16% | +$324K |
2018 Q1
2 quarters
|
|
23
SPS Commerce
SPSC
$3.05B
| $2.08M | 1.25% |
41,900
+200
| +0.5% | +$8.96K |
2018 Q1
2 quarters
|
|
24
Veracyte
VCYT
$3.49B
| $2.02M | 1.21% |
211,555
+60,700
| +40% | +$669K |
2018 Q1
2 quarters
|
|
25
CryoPort
CYRX
$855M
| $2M | 1.2% |
156,400
-500
| -0.3% | -$7.14K |
2016 Q1
10 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Perkins Capital Management held 144 positions worth $167M, up 19% from $140M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Perkins Capital Management deployed $12.7M of net new capital in Q3 2018, opening 17 new positions and adding to 44 existing holdings. Its largest new stake was Venus Concept: 240 shares worth $1.73M.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 62% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Tactile Systems Technology, an estimated $1.09M trimmed.
- Perkins Capital Management's largest Q3 2018 buy was Venus Concept: 240 shares worth $1.73M.
- Perkins Capital Management added most to IRIDEX in Q3 2018, an estimated $1.16M increase.
- Perkins Capital Management's biggest Q3 2018 reduction was Tactile Systems Technology, cutting an estimated $1.09M.
- Perkins Capital Management fully exited Invuity, Inc in Q3 2018, selling an estimated $1.22M.
- Perkins Capital Management's ten largest holdings make up 32% of its $167M portfolio in Q3 2018.
- Perkins Capital Management opened 17 new positions and closed 12 in Q3 2018.
- Perkins Capital Management's portfolio value rose 19% quarter-over-quarter to $167M.
Based on Perkins Capital Management's 13F filing for Q3 2018, filed 22 Oct 2018.